Bile duct adenocarcinoma
MONDO:0003193A carcinoma that arises from glandular epithelial cells of the bile duct
Also known as: bile duct adenocarcinoma
3321 clinical trials for this condition and its sub-types, 17 tagged with Bile duct adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Bile duct adenocarcinoma
-
Extrahepatic bile duct adenocarcinoma 2 trials · 409 incl. sub-types
7 sub-types
- Adenocarcinoma of gallbladder and extrahepatic biliary tract 6 trials · 374 incl. sub-types Sub-types →
- Ampulla of vater adenocarcinoma 11 trials · 42 incl. sub-types Sub-types →
- Extrahepatic bile duct clear cell adenocarcinoma 0 trials Sub-types →
- Extrahepatic bile duct mucinous adenocarcinoma 0 trials Sub-types →
- Extrahepatic bile duct signet ring cell carcinoma 0 trials Sub-types →
- Extrahepatic bile duct small cell adenocarcinoma 0 trials
- Papillary extrahepatic bile duct adenocarcinoma 0 trials
Most studied deeper sub-types
-
Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
Disease control OngoingThis phase 2 trial is testing whether adding either ramucirumab (a blood-vessel blocker) or merestinib (a cell-signal blocker) to standard chemotherapy (cisplatin + gemcitabine) can help people with advanced or metastatic biliary tract cancer live longer without their disease wor…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for bile duct cancer: targeted drug shows promise in early trial
Disease control OngoingThis study tests a drug called olaparib in 32 people with advanced bile duct cancer that has spread and has certain DNA repair gene mutations. Olaparib works by blocking enzymes that cancer cells need to grow. The main goal is to see how many patients are alive without their canc…
Phase 2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Keytruda takes on 15 advanced cancers in major trial
Disease control OngoingThis phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in people with 15 types of advanced solid tumors that have worsened after standard treatments. About 1,600 participants receive the drug to see if their tumors shrink or stop growing. The study also looks fo…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Can a special PET scan unlock a new way to treat Hard-to-Treat upper GI cancers?
Knowledge-focused OngoingThis study is testing whether a special PET scan using a tracer called 68Ga-PSMA can identify patients with advanced upper digestive tract cancers (like stomach or esophageal cancer) who might be eligible for a type of targeted radiation therapy called endoradiotherapy. The resea…
Phase 2 • Sponsor: Centre de recherche du Centre hospitalier universitaire de Sherbrooke • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC